- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06510582
Tratamento de hematoma subdural crônico com injeção intra-arterial de bevacizumabe (CHAI)
Tratamento de hematoma subdural crônico com injeção intra-arterial de Avastin® (Bevacizumabe): um ensaio clínico não randomizado e aberto de fase 1/2
The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH).
The main questions it aims to answer are:
- Is bevacizumab infusion safe in cSDH patients?
- Is bevacizumab infusion effective in treating cSDH?
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This protocol was originally proposed as a phase I/II trial. Phase 1 was completed; planned phase 2 was discontinued prior to initiation.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
New Jersey
-
Camden, New Jersey, Estados Unidos, 08103
- Cooper University Health Care
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Adult patients (≥18 years)
-
Radiographic evidence of chronic subdural hematoma, including
- Persistence of subdural blood more than 10 days after index traumatic injury or event
- Presence of mixed density blood
- Presence of subdural membranes
-
Can obtain informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.
Exclusion Criteria:
- Pregnant, breastfeeding, or unwilling to practice contraception during participation in the study.
- Patients with concomitant intracranial pathology other than subdural hematoma (e.g., intracranial malignancy).
- Patients with known hypersensitivity to bevacizumab.
- Patients with radiographic evidence of mass effect.
- Patients have focal neurological deficits attributed to subdural hematoma.
- Patient had craniotomy or burr hole operative procedures performed in preceding two weeks prior to onset of subdural hematoma.
- Secondary causes apart from trauma for the chronic subdural hematoma, such as underlying vascular abnormality or tumor.
- Emergent surgical evacuation is required for the patient.
- Non-convexity chronic subdural hematoma, as the middle meningeal artery will not supply this area.
- Coagulation abnormalities, including platelet count <100,000 and/or international normalized ratio of <1.5 despite attempts for correction.
- Patients with known contraindications for angiography. Patients with contrast allergy will be premedicated with diphenhydramine and steroids.
- Patient has known active systemic infection or sepsis.
- Patient has contradiction to anesthetic agents used for conscious sedation/monitored anesthesia care (MAC).
- Patient has life expectancy of less than six months due to comorbid terminal conditions.
- Patient has a premorbid modified Rankin score (mRS) of 5 or greater.
- Concurrent participation in another research protocol for investigation of an experimental therapy.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Phase 1 Unilateral cSDH/ 2mg/kg Arm
During phase 1, single 2mg/kg dose of bevacizumab to treat unilateral cSDH |
Single 2mg/kg dose of bevacizumab to treat unilateral cSDH |
|
Experimental: Phase 1 Bilateral cSDH/ 4mg/kg Arm
During phase 1, two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH |
Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants with Serious Adverse Events
Prazo: Up to 3 months after study treatment
|
Reported serious adverse events classified using MedDRA and CTCAE, in addition to treatment-related events and all other adverse events |
Up to 3 months after study treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of Hematoma Recurrence
Prazo: 3 months after study treatment and 6 months after study treatment
|
Rate of hematoma recurrence or progression requiring intervention and/or readmission |
3 months after study treatment and 6 months after study treatment
|
|
Rate of Complete Hematoma Resolution
Prazo: 3 months after study treatment and 6 months after study treatment
|
Rate of complete hematoma resolution compared to baseline on imaging |
3 months after study treatment and 6 months after study treatment
|
|
Rate of Partial Hematoma Resolution
Prazo: 3 months after study treatment and 6 months after study treatment
|
Rate of at least 50% or greater reduction in hematoma size from baseline on imaging |
3 months after study treatment and 6 months after study treatment
|
|
Change in Hematoma Size
Prazo: 3 months after study treatment and 6 months after study treatment
|
Change in hematoma size measured in millimeters on imaging |
3 months after study treatment and 6 months after study treatment
|
|
Change in Clinical Neurological Symptom Scale Scores: NIHSS
Prazo: 3 months after study treatment and 6 months after study treatment
|
Change in National Institutes of Health Stroke Scale (NIHSS) scores, scores range from 0 to 42, with higher scores indicating more severe neurological deficit |
3 months after study treatment and 6 months after study treatment
|
|
Change in Clinical Neurological Symptom Scale Scores: GCS
Prazo: 3 months after study treatment and 6 months after study treatment
|
Change in Glasgow Coma Scale (GCS) scores, ranging from 3 to 15 with lower score indicating more impaired consciousness |
3 months after study treatment and 6 months after study treatment
|
|
Change in Clinical Neurological Symptom Scale Scores: mRS
Prazo: 3 months after study treatment and 6 months after study treatment
|
Change in modified Rankin Scale (mRS) scores, ranges from 0-6 with higher score indicating worse functional outcome |
3 months after study treatment and 6 months after study treatment
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants with Anatomical Variants
Prazo: During the treatment procedure
|
Middle meningeal arteries with dangerous anastomoses observed on imaging |
During the treatment procedure
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Cadeira de estudo: Manisha Koneru, MD, The Cooper Health System
- Investigador principal: Jane Khalife, MD, The Cooper Health System
- Cadeira de estudo: Ajith J Thomas, MD, The Cooper Health System
Publicações e links úteis
Publicações Gerais
- Khalife J, Koneru M, Thomas AJ. Inflammation as a Key Driver for Chronic Subdural Hematomas. Stroke. 2026 Jul;57(7):1908-1919. doi: 10.1161/STROKEAHA.126.055340. Epub 2026 May 27.
- Khalife J, Koneru M, Tonetti DA, Shaikh HA, Jovin TG, Patel PD, Thomas AJ. Intra-arterial Selective Bevacizumab Administration in the Middle Meningeal Artery for Chronic Subdural Hematoma: An Early Experience in 12 Hemispheres. Stroke Vasc Interv Neurol. 2024 Jul 22;4(5):e001409. doi: 10.1161/SVIN.124.001409. eCollection 2024 Sep.
- Khalife J, Tonetti DA, Shaikh H, Jovin T, Patel P, Thomas A. Intraarterial Bevacizumab Administration Through the Middle Meningeal Artery for Chronic Subdural Hematoma. Stroke Vasc Interv Neurol. 2023 Feb 25;3(4):e000722. doi: 10.1161/SVIN.122.000722. eCollection 2023 Jul.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Ferimentos e Lesões
- Processos Patológicos
- Doença crônica
- Atributos da doença
- Hemorragia
- Trauma Craniocerebral
- Trauma, Sistema Nervoso
- Hemorragias Intracranianas
- Hemorragia Intracraniana Traumática
- Condições Patológicas, Sinais e Sintomas
- Hematoma Subdural
- Hematoma
- Hematoma Subdural Crônico
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Bevacizumabe
Outros números de identificação do estudo
- 23-154
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .